229 related articles for article (PubMed ID: 29880274)
21. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
[TBL] [Abstract][Full Text] [Related]
22. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
23. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
24. Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors.
Shin SJ; Kim T; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI; Kang M
Clin Genitourin Cancer; 2019 Dec; 17(6):e1137-e1146. PubMed ID: 31473122
[TBL] [Abstract][Full Text] [Related]
25. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
27. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry.
Tsimafeyeu I; Shatkovskaya O; Krasny S; Nurgaliev N; Varlamov I; Petkau V; Safina S; Zukov R; Mazhbich M; Statsenko G; Varlamov S; Novikova O; Zaitsev I; Moiseyev P; Rolevich A; Evmenenko A; Popova I; Kaidarova D; Vladimirova L
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1331. PubMed ID: 33369240
[TBL] [Abstract][Full Text] [Related]
29. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
30. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
[TBL] [Abstract][Full Text] [Related]
31. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
32. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
[TBL] [Abstract][Full Text] [Related]
33. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
34. Patterns of care for metastatic renal cell carcinoma in Australia.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S; Johnstone A; Gibbs P; Tran B
BJU Int; 2015 Oct; 116 Suppl 3():36-41. PubMed ID: 26204961
[TBL] [Abstract][Full Text] [Related]
35. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
36. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Tsimafeyeu I; Zolotareva T; Varlamov S; Zukov R; Petkau V; Mazhbich M; Statsenko G; Safina S; Zaitsev I; Sakaeva D; Popov A; Borisov P; Vladimirova L
Clin Genitourin Cancer; 2017 Dec; 15(6):e1069-e1072. PubMed ID: 28882737
[TBL] [Abstract][Full Text] [Related]
37. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland.
Weight CJ; Kim SP; Lohse CM; Cheville JC; Thompson RH; Boorjian SA; Leibovich BC
Eur Urol; 2011 Sep; 60(3):458-64. PubMed ID: 21514718
[TBL] [Abstract][Full Text] [Related]
38. Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium.
Nini A; Capitanio U; Larcher A; Dell'Oglio P; Dehò F; Suardi N; Muttin F; Carenzi C; Freschi M; Lucianò R; La Croce G; Briganti A; Colombo R; Salonia A; Castiglioni A; Rigatti P; Montorsi F; Bertini R
Eur Urol; 2018 May; 73(5):793-799. PubMed ID: 28917595
[TBL] [Abstract][Full Text] [Related]
39. Is observation a valid strategy in metastatic renal cell carcinoma?
Pickering LM; Mahgoub MO; Mukherji D
Curr Opin Urol; 2015 Sep; 25(5):390-4. PubMed ID: 26075569
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
